Review of CheckMate-214: Long-term follow-up in favorable risk subgroup
Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.
- Dr McKay: Please briefly review the key efficacy and safety data from the CheckMate-214 trial 8-year follow-up for treatment-naïve patients (Tannir NM, et al. J Clin Oncol. 2024) recently presented at ASCO GU 2024.
- What are the clinical implications of these data in your practice?
- In responders, how important is the durability of the response (OS and PFS) for both the intermediate/poor and favorable-risk groups?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
McGregor and Participants Discuss Impact of Drug Efficacy and Histology on nccRCC Care
October 17th 2024During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
Read More
